高盛发表报告指，康哲药业(00867.HK) 上半年收入45亿元人民币，按年升12.5%，低于该行预期的18%增长。三大核心VBP产品表现优于预期。尽管收入增长放缓，纯利仍按年升5%至9.86亿元人民币，大致符合该行预期，主要因销售开支低于预期，按年持平并由占销售35.6%降至32%。研发开支按年升76%，因公司持续扩张内部创新管线，每年新增10至15个新项目。面对持续反腐及医保控费的挑战性行业...
Source Link高盛发表报告指，康哲药业(00867.HK) 上半年收入45亿元人民币，按年升12.5%，低于该行预期的18%增长。三大核心VBP产品表现优于预期。尽管收入增长放缓，纯利仍按年升5%至9.86亿元人民币，大致符合该行预期，主要因销售开支低于预期，按年持平并由占销售35.6%降至32%。研发开支按年升76%，因公司持续扩张内部创新管线，每年新增10至15个新项目。面对持续反腐及医保控费的挑战性行业...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.